Login / Signup

Tumor glycolytic profiling through 18 F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC.

Saulo Brito SilvaCarlos Wagner S WanderleyJosé Flávio G MarinMariana Petaccia de MacedoEllen Caroline Toledo do NascimentoFernanda Frozoni AntonacioCaroline Sales FigueiredoMateus Trinconi CunhaFernando de Queiroz CunhaGilberto de Castro Junior
Published in: Therapeutic advances in medical oncology (2022)
F-FDG PET/CT are useful biomarkers for evaluating ICI therapy in advanced NSCLC.
Keyphrases
  • small cell lung cancer
  • advanced non small cell lung cancer
  • brain metastases
  • single cell
  • stem cells
  • epidermal growth factor receptor
  • bone marrow